9. COMMITMENTS AND CONTINGENCIES (Details Narrative) (USD $)	12 Months Ended
Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2012
Research and development expense	$ 17,000,145us-gaap_ResearchAndDevelopmentExpense	$ 12,681,049us-gaap_ResearchAndDevelopmentExpense	$ 10,368,695us-gaap_ResearchAndDevelopmentExpense
Rent expense, including amortization of deferred rent	2,650,829us-gaap_LeaseAndRentalExpense	2,651,460us-gaap_LeaseAndRentalExpense	2,659,532us-gaap_LeaseAndRentalExpense
Total deferred rent asset	5,277,939CVM_TotalDeferredRentAsset	4,733,865CVM_TotalDeferredRentAsset
Deferred rent asset, non-current	4,733,865CVM_DeferredRentNetOfCurrentPortion	5,448,381CVM_DeferredRentNetOfCurrentPortion
R & D deferred rent liability	6,387CVM_RDDeferredRentLiability	3,992CVM_RDDeferredRentLiability
Deferred rent liability	6,278CVM_DeferredRentLiability	12,412CVM_DeferredRentLiability
Ergomed Collaborative Arrangement
Research and development expense	$ 4,385,000	$ 838,000

- Definition

The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.

+ References+ Details